Focal and Segmental Glomerulosclerosis in a Multiple Myeloma Patient After Belantamab Mafodotin Therapy and Severe COVID-19 Infection: A Case Report

Mohamed Sabbah; Stephanie Nguyen; Maya Ouzegdouh; Sylvain Choquet; David Buob; Jean Jacques Boffa; Alexandre Cez; Laurent Garderet

doi:10.12659/AJCR.944681

01 November 2024 : Case report France

Focal and Segmental Glomerulosclerosis in a Multiple Myeloma Patient After Belantamab Mafodotin Therapy and Severe COVID-19 Infection: A Case Report

Unusual clinical course, Challenging differential diagnosis

Mohamed Sabbah^1ABCDEF, Stephanie Nguyen^1ACDE, Maya Ouzegdouh^1ADE, Sylvain Choquet^1ADE, David Buob^2BDE, Jean Jacques Boffa^3ADE, Alexandre Cez^3ADE, Laurent Garderet^4ABCDEF*

DOI: 10.12659/AJCR.944681

Am J Case Rep 2024; 25:e944681

Authors information Article notes Copyright and License information

Introduction Case Report Discussion Conclusions References:

Related articles Order reprints Share article Share by email

View HTML version

Figure 1. Kappa free light-chain levels decrease after the first injection of belantamab mafodotin.

Back to the Article

Focal and Segmental Glomerulosclerosis in a Multiple Myeloma Patient After Belantamab Mafodotin Therapy and Severe COVID-19 Infection: A Case Report

Your Privacy